KLK-targeted therapies for prostate cancer

Hannu Koistinen, Johanna Mattsson, Ulf-Håkan Stenman

Department of Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland

ABSTRACT

Alternative treatments are urgently needed for prostate cancer, especially to address the aggressive metastatic castration-resistant disease. Proteolytic enzymes are involved in cancer growth and progression. The prostate produces several proteases, the most abundant ones being two members of the kallikrein-related peptidase (KLK) family, prostate-specific antigen (PSA) and KLK2. Despite the wide use of PSA as a clinical marker, the function(s) of PSA and other KLKs in prostate cancer are poorly known. Hypothetic roles of KLKs in prostate cancer include activities that may both promote and inhibit cancer growth and metastasis, including the antiangiogenic activity of PSA. Thus it may be possible to control prostate cancer growth by modulating the proteolytic activities of KLKs. PSA and KLK2 are especially attractive targets for prostate cancer treatment because of their proposed roles in tumor development and inhibition of angiogenesis in combination with their prostate selective expression. So far the number of molecules affecting selectively the activity of KLKs is limited and none of these are used to treat prostate cancer. Prodrugs that, after cleavage of the peptide part by PSA or KLK2, release active drug molecules, and PSA-targeted therapeutic vaccines have already been tested clinically in humans and the first results have been encouraging. Although KLKs are attractive targets for prostate cancer treatment, much remains to be done before their potential can be fully elucidated. The objective of this review is to address the current state of the KLKs as novel therapeutic targets for prostate cancer treatment.
INTRODUCTION

Prostate cancer is a considerable health care problem. With 900,000 new cases and about 260,000 deaths worldwide in 2008, it is the second most frequently diagnosed cancer and the sixth most common cause of cancer death in men [1]. In the UK, the lifetime risk of developing prostate cancer is estimated to be 1 in 8 (Cancer Research UK). Since the approval of prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3) test by FDA in 1986, PSA has been the most widely used cancer marker [2]. However, extensive screening with PSA has lead to detection and unnecessary treatment of cancers that would not have surfaced clinically without screening [2]. Prostate cancer often presents as a multi-focal tumor with various degrees of aggressiveness. Because of the widespread use of screening, most prostate cancers are presently detected at an early stage and have favorable prognosis. While most patients can be cured by radical prostatectomy or radiotherapy, most of them, and 10-20% within 5 years, become resistant to this therapy, i.e., develop castration-resistant prostate cancer (CRPC) [4]. Currently there is no cure for these cancers [5]. While CRPCs respond to some treatment modalities, the effect on survival is generally modest, i.e., some months. Therefore, it is important to develop alternative treatments that are either curative, prevent the development of CRPC and/or formation of metastatic lesions that eventually kill the patients, or to slow down the growth of small tumors, in order to prevent them from surfacing clinically within the lifetime of the patient. Proteolytic enzymes (proteases), including 15 members of the kallikrein-related peptidase (KLK) family, are potential targets for treatment of prostate cancer [6]. Despite the widespread use of PSA as a clinical marker, the function(s) of PSA and other KLKs in prostate cancer are poorly known [7]. While several KLKs may be involved in prostate cancer development, efforts to target them for treatment of prostate cancer have concerned the two major proteases produced in prostate, i.e., PSA and KLK2. Thus this review will focus mainly on these KLKs and their use as novel therapeutic targets for prostate cancer treatment.

PROTEASES IN CANCER

Since the discovery of the role of proteases in food degradation, proteases have been found to be involved in almost all biological pathways and networks, performing several essential functions in all living organisms, from fertilization and development to normal physiology [8,9]. Proteases (also called peptidases or proteolytic enzymes) may exhibit highly selective substrate cleavage or have broader specificity. About 600 human proteases, which are collectively called the degradome, representing ~2% of the whole human genome are known [10]. Among the serine proteases, KLKs form a family of 15 trypsin- and chymotrypsin-like proteases [11,12]. Protease activity is controlled by several mechanisms, including regulation of gene expression, activation of their inactive pro-forms (zymogens) either autocatalytically or by other proteases, inhibition of their activity by endogenous protease inhibitors, and phosphorylation [8,13]. Many proteases, including those of the KLK family, act in cascades or networks, which facilitates signal amplification and stringent regulation of their activity [14]. Alterations in proteolytic systems underlie several pathological conditions, including cancer, and proteases have been found to play a significant role at virtually all stages of tumor progression [9]. The roles of proteases in cancer have been widely studied since the discovery of their
role in cancer cell invasion, which is a prerequisite for tumor invasion and metastasis formation. In addition to degrading extracellular matrix proteins and adhesion molecules facilitating cell invasion, proteases have several other functions relevant for cancer, including activation of protease-activated receptors (PARs) and regulation of the activity of other signaling molecules, like kinases and growth factors [8,13,15]. Cancer has been thought to be primarily associated with increased proteolytic activity and while this is true for many proteases, some proteases exert opposite effects, such as acting as tumor suppressors by suppressing angiogenesis or inducing apoptosis [16,17].

Expression of KLKs in prostate cancer

The prostate produces several proteases, the most abundant ones being two KLKs, PSA and KLK2 [18]. Shaw and Diamandis reported that all 15 KLKs are expressed in the prostate at the mRNA level [18]. In tissue extracts they found, in addition to KLK2 and PSA, KLK1, -4, -5, -9, -11, -13, -14 and -15. PSA is expressed in differentiated luminal epithelial cells of the prostate and secreted into seminal fluid. The levels in extracellular fluid of the prostate are up to 2 µM or in prostate tissue 10 mg/g of tissue [18,19]. Most of this PSA is enzymatically active [19]. However, when active PSA and other KLKs reach circulation, they are rapidly inactivated by protease inhibitors that are present in vast excess in circulation. While PSA is a major constituent of seminal fluid, only a minor part of it leaks out into circulation. Interestingly, the tissue concentrations of PSA are lower in malignant than in normal prostatic epithelium and they are further reduced in poorly differentiated (high Gleason grade) tumors [20]. In spite of this, PSA is the best cancer marker presently available [2,7]. This is based on increased leakage into circulation from malignant prostatic tissue that has lost connection with the prostatic ducts [21]. The clinical use of PSA determinations has been reviewed in several recent articles [22,23]. Among the KLKs, KLK2 has attracted most interest after PSA, due to its prostate specificity and relatively high expression levels [18]. Contrary to PSA, KLK2 expression in prostate cancer is higher than in benign prostate [23,24]. The ratio between hK2 and PSA mRNA increases with increasing grade [25].

Noteworthy, single nucleotide polymorphisms (SNPs) in KLK genes have been shown to be associated with prostate cancer [26]. Some of these SNPs affect the expression levels of KLKs. However, apart from these genetic polymorphisms and hormonal regulation [11], the mechanisms behind the altered regulation of KLK expression in tumors still remains largely unsolved.

Functions of KLKs in prostate cancer

The suggested functions of KLKs include both those that promote and inhibit tumor growth and metastasis [7,11,12,27]. The physiological function of PSA, and perhaps also other prostatic KLKs, is to promote sperm motility by dissolving the seminal clot formed after ejaculation by cleaving semenogelins. KLKs are also able to cleave several prostate cancer related substrates, at least in vitro [11]. However, hypothetic functions based on in vitro cleavage should be interpreted with caution. In clinical studies, low PSA levels in prostate cancer tissue are associated with poor prognosis [20,28], while high PSA levels are associated with low blood vessel density [29,30]. However, the PSA concentrations in serum are sometimes increased decades before the development of otherwise detectable tumors [31,32]. This suggests that PSA may initiate or facilitate early cancer development.

Cancer cells have to acquire several biological capabilities during the multistep development of tumors described by Hanahan and Weinberg
in *Hallmarks of Cancer* [33]. Several described or hypothesized functions of KLKs are relevant for these effects [7]. The ability to proliferate and evade growth-suppressing signals is one of the essential properties of cancer cells. Several studies suggest that PSA and other KLKs may promote the growth of prostate cancer by stimulating cell proliferation [34,35]. Furthermore, PSA has been found to promote the growth of prostate cancer xenograft tumors [34]. In contrast to these studies, Bindukumar *et al.* [37] found that subcutaneously administered PSA reduced the growth of xenograft tumors in mice. Several KLKs have been found to activate growth-factors and PARs [11,15], which lead to a wide array of responses, including promotion of cancer cell growth and invasion. In addition to increasing cell proliferation, PSA has been shown to reduce apoptosis [35], which is also essential for cancer development.

Like all tissues, tumor needs nutrients and oxygen and ability to remove waste and carbon dioxide in order to grow and survive [33]. This requires vascularization and thus tumors need to develop new blood vessels in order to grow beyond a size of 2-3 mm³ [37]. Prostate cancer grows unusually slowly after reaching this size, which corresponds to the time when it can be detected by prostate biopsy of men with elevated serum concentrations of PSA [31]. The slow growth of prostate cancer could be dependent on the antiangiogenic activity of PSA. Several studies have addressed the antiangiogenic role of PSA, which has been demonstrated in cell culture models at sub-physiological PSA concentrations [16,38,39]. In a pioneering study by Fortier *et al.*, PSA was shown to inhibit endothelial cell tube formation, growth, invasion and migration [16]. They further showed that subcutaneous administration of PSA inhibits angiogenesis in an *in vivo* model of blood vessel growth [38]. The mechanism by which PSA exerts its antiangiogenic effect is unclear. Even the dependence on enzymatic activity is controversial [38]. However, our studies strongly suggest that PSA activity is needed for the antiangiogenic activity, as the enzymatic activity of different PSA forms present in seminal fluid correlates with the antiangiogenic activity [39]. Furthermore, inhibition of PSA by small molecule inhibitors or an antibody abolishes the antiangiogenic activity [40], while the stimulation of PSA activity by peptides enhanced it [41].

Several KLKs, like PSA and KLK2, are able to degrade extracellular matrix proteins and activate other extracellular matrix degrading proteases or inactivate their inhibitors [11,14]. These studies suggest that KLKs are involved in proteolytic cascades facilitating prostate cancer growth and metastasis [14]. Indeed, PSA-treatment has been found to increase invasion of prostate cancer cells *in vitro* [42]. Other studies suggest that PSA may play a role in the development of bone metastases (reviewed in [11,43]).

Knockout studies of PSA or KLK2 have not been performed as mice and other animals used for such studies do not have genes encoding PSA or KLK2 [11]. Most studies aiming to solve the functions of KLK2, PSA, and other KLKs have utilized cancer cell lines. However, the *in vitro* growth characteristics of these cells may not necessarily predict tumorigenicity and different cell lines may show very different responses [7]. Furthermore, cancer cells grown in an isolated environment behave very differently from those in tumors and in contact with extracellular matrix and stromal cells [44]. Transgenic mice expressing PSA and/or KLK2 in the prostate have been developed. In these, neither PSA nor KLK2 have been found to initiate cancer or cause any morphological changes [45]. However, the PSA levels in these are about 1000-fold lower than those in the human prostate.

Taken together, these studies suggest that PSA and other KLKs may affect tumor growth and
perhaps even initiate cancer development. The effects of KLKs may be different at different stages of tumor growth, e.g., PSA may favor tumor development at early stages of cancer, for example by activating growth factors, but at later stages it may inhibit tumor growth by its antiangiogenic activity [7].

**KLK-TARGETED THERAPIES FOR PROSTATE CANCER**

Recently, proteases have been estimated to represent 5-10% of the potential drug targets [46,47] but the number of new approved protease inhibitors is still limited [48]. A problem with proteases as drug targets is the lack of specificity. Thus, inhibitors tend to react with similar proteases affecting a broad range of protease activities that are crucial for normal physiology. For example, lack of specificity was a major reason for the failure of early matrix metalloprotease (MMP)-inhibitors, as they also inhibited MMPs that are needed for normal tissue function, or act as tumor suppressors [46,47,17].

PSA and KLK2 are attractive targets for prostate cancer treatment because of their possible roles in tumor development, metastasis and inhibition of angiogenesis, and their prostate selective expression, which together with the lack of active forms in circulation makes systemic effects unlikely. Furthermore, as their proposed physiological function is related to liquefaction of the seminal fluid clot, their targeting is not likely to cause severe side-effects other than those related to fertility. In addition to PSA and KLK2, KLK4 is also a potential target for prostate cancer treatment [49]. KLK4 is overexpressed in prostate cancer, promotes cell proliferation and cleaves several cancer associated substrates, including PARs [11,50,51].

Several naturally occurring proteins, including serpins, Kazal-type serine protease inhibitors and α₂-macroglobulin, inhibit KLKs [49,52]. However, these are rather non-specific inhibitors. So far the number of molecules affecting selectively the activity of individual KLKs is very limited and none of these are used to treat prostate cancer [6,49,52]. For PSA, both activity-stimulating and inhibiting compounds have been developed, while for KLK2 and KLK4 only inhibitors have been described (Table). Prodrugs that are activated by PSA or KLK2, and PSA-targeted therapeutic vaccines have already been tested clinically in humans and preliminary results are encouraging [53,54] (Table).

**PSA inhibitors and stimulators**

Several peptide-based or small molecule inhibitors for PSA have been described (reviewed in [6,27,49,52]). These have been found either by high-throughput screening or by rational drug design. Several antibodies that inhibit or stimulate PSA activity have also been described [55]. Some of these inhibitors have been tested in prostate cancer relevant models and found to inhibit antiangiogenic activity of PSA in a cell culture model [40], inhibit the growth of prostate cancer cell lines or exert a small inhibitory effect on xenograft tumor growth [56]. It should be noted that the specificity of these inhibitors has not been thoroughly characterized.

Since PSA shows antiangiogenic activity and, thus could inhibit development of prostatic tumors, we have been interested in molecules that stimulate the activity of PSA. By screening of almost 50,000 drug-like small molecules, we found some PSA inhibitors but did not identify compounds that stimulate PSA activity [40]. While small molecule drugs have several advantages as compared to peptides, their specificity for similar proteases is more limited. Furthermore, only 30-50% of the targets that represent an opportunity for therapeutic intervention have been suggested to be amenable to traditional small molecule approaches [57]. Thus, we have used phage-display to develop peptides,
### Table Summary of the major findings on different KLK targeted therapies for prostate cancer

| Strategy/target | Agent | Major outcome/therapeutic effect<sup>a</sup> | References |
|-----------------|-------|------------------------------------------|------------|
| **Inhibitors**  | PSA   | Inhibit prostate cancer cell and xenograft tumor growth; inhibit antiangiogenic activity of PSA | 6,27,40,49, 52,56 |
| PSA             | modified serpin<sup>b</sup>, peptide | Reduce xenograft tumor growth<sup>b</sup> | 63-66 |
| PSA             | peptide | Not determined | 68,69 |
| **Stimulators** | PSA   | Stimulate antiangiogenic activity of PSA in cell model | 58-62 |
| **Prodrugs**    | PSA   | Selectively kills PSA-producing cells in vitro; selective antitumor effect on PSA-producing tumor xenografts in mice and monkeys; significant improvement of symptoms in patients with benign prostatic hyperplasia with only mild, locally limited side effects | 73-84 |
| PSA             | KLK2   | Significant antitumor effect in tumor xenografts in vivo, but prolonged administration caused local toxic effect; less effective than similar PSA-activated prodrug | 85 |
| **Vaccination** | PSA   | Safe in phase I and II studies, showing prostate specific T lymphocyte responses and benefit for some of the patients | 53-54 |

<sup>a</sup> The mentioned outcomes and therapeutic effects may be valid only for some of the agents for a given strategy and target.

<sup>b</sup> The agent, modified serpin, not specific for KLK2.
which stimulate the activity of PSA several fold at µM concentrations [58,59]. These peptides also stimulate PSA-activity towards protein substrates but they do not affect the activity of several enzymatically or structurally related proteases (Mattsson et al., unpublished data) [59]. The use of peptides for drug discovery is a rapidly emerging field. The pharmacokinetic and other properties of peptides can be modified and they can serve as starting structures for development of peptidomimetics. We have been able to significantly improve the stability of some peptides stimulating PSA activity and created the first pseudopeptides, in which parts of the peptide have been replaced by non-peptidic structures without loss of bioactivity [60,61]. We hypothesize that modified peptides or peptidomimetic compounds based on these can be used for imaging and proof of principle studies, and eventually for treatment of prostate cancer. The peptides enhance the antangiogenic activity of PSA in cell culture models [41] but in preliminary animal studies, the first generation peptides have not shown any major effect on tumor growth (our unpublished results). This is not surprising as the peptides are quickly excreted. Using pharmacophore-based virtual screening we have recently identified the first small drug-like molecule that stimulates PSA activity [62].

**KLK2 and KLK4 inhibitors**

Since many cancers, including prostate cancer, are associated with increased activity of several proteases, inhibitors, in addition to those for PSA, have been developed for KLK2 and KLK4 for the targeting of prostate cancer. Cloutier et al. have used phage-display to screen a library of variants of α1-anti-chymotrypsin (ACT), which inhibits several proteases. They identified a modified version of ACT that showed selectivity towards KLK2 [63], but it was later found to also inhibit several other KLKs, especially KLK4, KLK5 and KLK14 [64]. This molecule, called MD-PK67b, has been shown to reduce the growth of prostate cancer xenograft tumors producing KLK2. Further clinical studies, including evaluation of safety in humans, have been initiated [64].

As our phage-display approach was successful with PSA, we also developed peptide inhibitors for KLK2 using this approach [65]. While all of the PSA-stimulating peptides were cyclic containing one or two disulfide-bridges, all the KLK2 inhibiting peptides were identified in linear peptide libraries. The identified peptides inhibited KLK2 at µM concentrations. Like with PSA-stimulating peptides, we have been able to significantly improve the stability of the KLK2-inhibitory peptides [66].

Sunflower trypsin inhibitor (SFTI), which is a 14 amino acid residue cyclic peptide structurally similar to Bowman-Birk family of serine protease inhibitors, is a potent and broad-range protease inhibitor [49,67]. Recently, SFTI has been modified to selectively and efficiently inhibit KLK4, using a combination of molecular modeling and substrate screening [68], and further in silico screening of inhibitor variants in complex with KLK4 or trypsin [69]. Although promising results with the SFTI-based KLK4 inhibitor have been obtained using ovarian cancer models [70], its effect on prostate cancer have not yet been reported.

**PSA- and KLK2-activated prodrugs**

Perhaps the most promising results concerning the use of KLKs in prostate cancer treatment have been obtained using prodrugs that are activated by PSA or KLK2. Protease-activated prodrugs are promising for targeted delivery of drugs into a specific tissue. The inactive prodrug consists of a toxic drug molecule conjugated to a peptide. The prodrug is activated in the target tissue through cleavage of the peptide moiety
by a specific protease leading to release of the active drug molecule [71,72]. Thus, the effect of the drug is directed to a specific tissue. PSA and KLK2 are well suited as prodrug activators as they have highly tissue specific expression, i.e., significant amounts of active PSA and KLK2 are found only in the prostate [6,18].

Several PSA-activated prodrugs have been developed using peptide sequences that are highly selective for PSA [73,74]. Drug molecules conjugated to these peptides include doxorubicin [73-75], vinblastine [76], 5-fluorodeoxyuridine [77], thapsigargin [78] and paclitaxel [79]. A doxorubicin conjugated prodrug L-377,202 selectively killed PSA-producing human prostate cancer cells in vitro and was 15 times more effective than conventional doxorubicin at inhibiting the growth of human prostate tumor xenografts in vivo [74]. Another PSA-activated prodrug, PRX302, with the bacterial toxin precursor proaerolysin, showed selective antitumor effect on PSA-producing tumor xenografts in mice, caused extensive damage to PSA-producing prostate cells in monkeys and showed no toxicity in other tissues [80]. These two PSA-activated prodrugs have been taken to phase I and II clinical trials, where both were well tolerated, although L-377,202 caused neutropenia at higher doses [75]. Intraprostatic injections of PRX302 lead to significant improvement of symptoms in patients with benign prostatic hyperplasia while only mild, locally limited side effects were reported [81].

Recent studies of PSA-activated prodrugs report utilization of cell penetrating peptides to deliver drugs inside prostate cancer cells [82], development of prodrug modifications using e.g. albumin as a drug carrier [83] and synthesis of fusion peptides with multiple specificities to target the drug effect to the cells that express specific receptors [84].

A thapsigargin-based prodrug has been developed for KLK2 [85]. A prodrug with a KLK2 peptide substrate conjugated to the thapsigargin analog, L12ADT, showed a significant antitumor effect in human prostate tumor xenografts in vivo, but prolonged administration caused local toxic effects [85]. Moreover, the antitumor effect was only modest when compared to a similar PSA prodrug with thapsigargin.

**PSA-targeted therapeutic vaccines**

Prostate cancer is considered an attractive target for development of therapeutic vaccines as it expresses several prostate-specific proteins and generally grows very slowly. Indeed, several vaccination strategies have been established, some of which target PSA (reviewed in [53,54]). Usually these vaccines also target other antigens in order to improve the immune response. For PSA, viral and DNA-based vaccines have been used, both encoding PSA and, usually, other antigens. These vaccines have been found to be safe in phase I and II studies, showing prostate specific T lymphocyte responses and, at least in some cases, some benefit for the patients [53,54]. It seems that these vaccines would be especially beneficial for patients with early-stage disease but results from phase III studies are not available yet.

**CONCLUSIONS**

PSA is an established marker for prostate cancer and several other KLKs are potential markers. As circulating PSA level is often used as a surrogate marker for tumor burden in preclinical and clinical studies [73-76,80,83], and more importantly to monitor relapse in patients, it would be important to address whether KLK targeted therapies could affect PSA levels also otherwise than by affecting the volume of the PSA producing tumor tissue. This is possible as PSA-targeted activity modulators and vaccination may affect, through several mechanisms,
the circulating PSA levels and also the detection of PSA by immunoassay. While in prodrug studies PSA seems to be a good marker for tumor burden, the therapy has also been found to induce initial leakage of PSA into circulation [81], perhaps because of tissue destruction.

While conclusive evidence for the roles of the KLKs in prostate cancer development is still lacking, KLKs expressed in the prostate are likely to have functional role(s) making them potential targets for treatment of prostate cancer. We have proposed that PSA promotes the growth of small tumors, but may inhibit development of large tumors at the stage when new blood vessels are needed [7]. In addition to PSA and KLK2, some other KLKs, like KLK4, are also potential targets for prostate cancer treatment. However, these KLKs have been less studied and their expression is not as restricted to the prostate as that of KLK2 and PSA. Therefore development of treatment based on these is more challenging. While several inhibitors for PSA and KLK2, and stimulators for PSA have been developed, their efficacy has not yet been tested in higher primates or humans. Some of these compounds have been promising in cell culture and mouse xenograft tumor models. However, the models used so far have several limitations and do not reflect the complexity of human prostate cancer. Furthermore, the specificity of the compounds has not been fully elucidated. Prodrugs that are activated by PSA or KLK2 have been tested clinically in humans with encouraging preliminary results. It is foreseen that these prodrugs, along with vaccines targeting PSA, may be the first KLK-based treatment modalities for prostate cancer. In conclusion, KLKs are attractive targets for prostate cancer treatment, but much remains to be done before their potential can be fully harnessed to treat prostate cancer.

**DISCLOSURES**

Ulf-Håkan Stenman holds patents for KLK-activity modulating peptides. Hannu Koistinen and Johanna Mattsson have nothing to disclose.

**REFERENCES**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L and Ekman P. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl 2005;216:64-81.
3. Ward JF and Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005;2:174-82.
4. Kirby M, Hirst C and Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180-92.
5. Tammela TL. Endocrine prevention and treatment of prostate cancer. Mol.Cell.Endocrinol. 2012;360:59-67.
6. Sotiropoulou G and Pampalakis G. Targeting the kallikrein-related peptidases for drug development Trends Pharmacol Sci 2012;33:623-634.
7. Koistinen H and Stenman UH. PSA (Prostate-Specific Antigen) and other Kallikrein-related Peptidases in Prostate Cancer. In: Kallikrein-related peptidases, Vol. 2: Novel cancer-related biomarkers (Eds: Magdolen,V. Sommerhoff, C.P . Fritz, H. Schmitt, M.), De Gruyter 2012, pp. 61-81.
8. Turk B, Turk du SA and Turk V. Protease signalling: the cutting edge. EMBO J 2012;31:1630-1643.
9. Lopez-Otin C and Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008;283:30433-30437.
10. Quesada V, Ordonez GR, Sanchez LM, Puente XS and Lopez-Otin C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res 2009;37:D239-43.
11. Lawrence MG, Lai J and Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus Endocr Rev 2010;31:407-446.
12. Borgono CA and Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890.
13. Lopez-Otin C and Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 2010;10:278-292.

14. Sotiropoulou G, Pampalakis G and Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009;284:32989-32994.

15. Oikonomopoulou K, Diamandis EP and Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem 2010;391:299-310.

16. Fortier AH, Nelson BJ, Grella DK and Holaday JW. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 1999;91:1635-40.

17. Lopez-Otin C and Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8.

18. Shaw JL and Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53:1423-32.

19. Denmeade SR, Sokoll LJ, Chan DW, Khan SR and Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1-6.

20. Abrahamsson PA, Lilja H, Falkmer S and Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988;12:39-46.

21. Stenman UH. Prostate-specific antigen, clinical use and staging: an overview. Br J Urol 1997;79 Suppl 1:53-60.

22. Lilja H, Ulmert D and Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78.

23. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ and Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011;50 Suppl 1:61-75.

24. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ and Bostwick DG. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.

25. Lintula S, Stenman J, Bjartell A, Nordling S and Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue Prostate 2005;63:324-329.

26. Batra J, O’Mara T, Patnala R, Lose F and Clements JA. Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biol Chem 2012;393:1365-90.

27. LeBeau AM, Kostova M, Craik CS and Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biol Chem 2010;391:333-343.

28. Stege R, Grande M, Carlstrom K, Tribukait B and Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000;6:160-5.

29. Papadopoulos I, Sivridis E, Giatromanolaki A and Koukourakis MI. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 2001;7:1533-8.

30. Ben Jemaa A, Bouraoui Y, Sallami S, Banasr A, Ben Rais N, Ouertani L, Nouira Y, Horchani A and Oueslati R. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res 2010;29:171.

31. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L and Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.

32. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, Bjartell AS, Scardino PT, Ulmert D and Vickers AJ. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011;117:1210-1219.

33. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.

34. Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT and Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate 2011;71:1595-1607.

35. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC and Chang C. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 2008;68:7110-7119.

36. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawsinski E and Chadha KC. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005;7:241-52.

37. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.

38. Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM and Nelson BJ. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 2003;56:212-9.

39. Mattsson JM, Valmu L, Laakkonen P, Stenman UH and Koistinen H. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate 2008;68:945-54.
40. Koistinen H, Wohlfahrt G, Mattsson JM, Wu P, Lahdenpera J and Stenman UH. Novel small molecule inhibitors for prostate-specific antigen. Prostate 2008;68:1143-51.

41. Mattsson JM, Narvanen A, Stenman UH and Koistinen H. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity. Prostate 2012;72:1588-1594.

42. Webber MM, Waghray A and Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1995;1:1089-94.

43. Williams SA, Singh P, Isaacs JT and Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007;67:312-29.

44. Bissell MJ and Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-329.

45. Williams SA, Xu Y, De Marzo AM, Isaacs JT and Denmeade SR. Prostate-specific antigen antibodies (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. Prostate 2010;70:788-796.

46. Overall CM and Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.

47. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5:785-99.

48. Drag M and Salvesen GS. Emerging principles in protease-based drug discovery. Nat.Rev.Drug Discov. 2010;9:690-701.

49. Swedberg JE, de Veer SJ and Harris JM. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biochem 2010;391:357-374.

50. Mize GJ, Wang W and Takayama TK. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 2008;6:1043-51.

51. Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielson HE and Saattcioglu F. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 2007;67:5221-5230.

52. Goettig P, Magdolen V and Brandstetter H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 2010;92:1546 -1567.

53. Geary SM and Salem AK. Prostate cancer vaccines: Update on clinical development. Oncoimmunology 2013;2:e24523.

54. Joniau S, Abrahamsson P, Bellmunt J, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H and Osanto S. Current Vaccination Strategies for Prostate Cancer. Eur Urol 2012;61:290-306.

55. Nilsson O, Andersson I, Peter A and Karlsson B. Characterization of antibodies to prostate-specific antigen. Tumour Biol 1999;20 Suppl 1:43-51.

56. LeBeau AM, Singh P, Isaacs JT and Denmeade SR. Potent and Selective Peptidyl Boronic Acid Inhibitors of the Serine Protease Prostate-Specific Antigen. Chem Biol 2008;15:665-674.

57. Robinson JA, Demarco S, Gombert F, Moehle K and Obrecht D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today 2008;13:944-51.

58. Koistinen H, Narvanen A, Pakkala M, Hekim C, Mattsson JM, Zhu L, Laakkonen P and Stenman UH. Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem 2008;389:633-42.

59. Wu P, Leinonen J, Koivunen E, Lankinen H and Stenman UH. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 2000;267:6212-20.

60. Meinderker K, Weisell J, Pakkala M, Tadd AC, Hekim C, Kallionppa R, Widell K, Stenman U, Koistinen H, När-vän H, Vepsäläinen J, Luthman K and Wallén EAA. Pseudopeptides with a centrally positioned alkene-based disulphide bridge mimic stimulus kallikrein-related peptidease 3 activity. MedChemComm 2013;4:549.

61. Meinderker K, Pakkala M, Weisell J, Stenman U, Koistinen H, När-vän H and Wallén EAA. Replacement of the Disulfide Bridge in a KLK3-Stimulating Peptide Using Orthogonally Protected Building Blocks. ACS Medicinal Chemistry Letters 2014; 5:162-5. .

62. Harkonen HH, Mattsson JM, Maatta JA, Stenman UH, Koistinen H, Matero S, Windshugel B, Poso A and Lahtela-Kakkonen M. The discovery of compounds that stimulate the activity of kallikrein-related peptidase 3 (KLK3). ChemMedChem 2011;6:2170-2178.

63. Cloutier SM, Kundig C, Felber LM, Fatlah OM, Chagas JR, Gygi CM, Jichlinski P, Leisinger HJ and Deperthes D. Development of recombinant inhibitors specific to human kallikrein 2 using phage-display selected substrates. Eur J Biochem 2004;271:607-13.

64. Deperthes D and Kündig C. Kallikrein-related Peptidases as Pharmaceutical Targets. In: Kallikrein-related peptidases, Vol. 1: Characterization, regulation, and interactions within the protease web (Eds: Magdolen,V. Sommerhoff, C.P. Fritz, H. Schmitt, M.), De Gruyter 2012, pp. 161-186.

65. Hekim C, Leinonen J, När-vän A, Koistinen H, Zhu L, Koivunen E, Väisänen V and Stenman UH. Novel peptide inhibitors of human kallikrein 2. J Biol Chem 2006;281:12555-60.
66. Pakkala M, Hekim C, Soininen P, Leinonen J, Koistinen H, Weissel J, Stenman UH, Vepsäläinen J and Närvänänen A. Activity and stability of human kallikrein-2–specific linear and cyclic peptide inhibitors. J Pept Sci 2007;13:348-53.

67. Luckett S, Garcia RS, Barker JJ, Konarev AV, Shewry PR, Clarke AR and Brady RL. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J Mol Biol 1999;290:525-33.

68. Swedberg JE, Nigon LV, Reid JC, de Veer SJ, Walpole CM, Stephens CR, Walsh TP, Takayama TK, Hooper JD, Clements JA, Buckle AM and Harris JM. Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. Chem Biol 2009;16:633-43.

69. Swedberg JE, de Veer SJ, Sit KC, Rebold CF, Buckle AM and Harris JM. Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network. PLoS One 2011;6:e19302.

70. Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM and Clements JA. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 2013;8:e57056.

71. Bildstein L, Dubernet C and Couvreur P. Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev 2011;63:3-23.

72. Choi KY, Swierczewska M, Lee S and Chen X. Pro tease-activated drug development. Theranostics 2012;2:156-178.

73. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV and Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 1998;58:2537-40.

74. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McMavoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Garsky VM, Freidinger R, Oliff A and Jones RE. A peptide-doxorubicin ‘prodrug’ activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 2000;6:1248-52.

75. DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P and Yao SL. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20:1874-879.

76. DeFeo-Jones D, Brady SF, Feng DM, Wong BK, Bolyar T, Haskell K, Kiefer DM, Leander K, McMavoy E, Lumma P, Pawluczyk JM, Wai J, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Garsky VM, Freidinger R, Oliff A and Jones RE. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Mol Cancer Ther 2002;1:451-459.

77. Mhaka A, Denmeade SR, Yao W, Isaacs JT and Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett 2002;12:2459-2461.

78. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB and Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990-1000.

79. Kumar SK, Williams SA, Isaacs JT, Denmeade SR and Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem 2007;15:4973-84.

80. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT and Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376-85.

81. Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG and Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 2013;189:1421-1426.

82. Goun EA, Shinde R, Dehnert KW, Adams-Bond A, Wender PA, Contag CH and Franc BL. Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. Bioconjug Chem 2006;17:787-796.

83. Elsadek B, Graeser R, Esser N, Schafer-Obodozie C, Abu Ajaj K, Unger C, Warnecke A, Saleem T, El-Melegy N, Madkor H and Kratz F. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer 2010;46:3434-3444.

84. Li B, Zhang LJ, Zhang ZL, Long M, Ren JH, Lin F, Wang X, Wei JX, Dong K and Zhang HZ. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy. Anticancer Drugs 2011;22:213-222.

85. Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT and Denmeade SR. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 2006;66:358-68.